Professor Bernard Begaud, pharmacologist, former president of the University of Bordeaux, chaired the monitoring committee for clinical trials within the French Medicines Agency (ANSM) for more than fifteen years. He returns for Release on chloroquine, and points to the inconsistency and lack of coordination of the trials in progress.
After three months of waiting, do we finally know if Professor Raoult’s treatment is effective or not?
To date, we have no scientific confirmation, so we cannot answer either yes or no. Partial results seem to indicate that hydroxychloroquine does not live up to its promises … Few trials have tested it in dual therapy, no doubt for fear of increasing cardiac toxicity.
But still, isn’t knowing clearly in early May problematic?
It is indeed incredible. Crises always reveal the weaknesses of a system; this highlights several major dysfunctions. The drug is one of the weak points
Liberation reserves this article for its subscribers
To continue reading, subscribe
for 2 months
100% digital offer
Do you already have a subscribed account?
- All our articles in
- The newspaper in version
digital the day of its publication
- Our newsletters
- RaJeux, our app from